CommercialCoverageMedium impact
Duchenne Muscular Dystrophy (DMD)
Blue Cross & Blue Shield of Mississippi·MS · Neurology, Pediatrics, Family Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated its Duchenne Muscular Dystrophy policy, removing coverage for Elevidys (gene therapy) in non-ambulatory patients and now only considering it 'not medically necessary' rather than 'investigational' for ambulatory patients. Four other DMD medications remain investigational with no coverage.
Action Required
Immediately: Update prior authorization workflows to reflect that Elevidys (J1413) is now 'not medically necessary' (rather than investigational) for ambulatory DMD patients and is no longer covered for non-ambulatory patients. Ensure billing staff understand all five DMD medications (J1413, J1426, J1427, J1428, J1429) require PA review and will likely be denied. Verify formulary coverage for each patient's specific benefit plan before prescribing.